

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Cutia Therapeutics**

**科笛集团**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2487)**

**(1) CHANGE OF COMPANY SECRETARY,  
AUTHORISED REPRESENTATIVE, PROCESS AGENT; AND  
(2) CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

**CHANGE OF COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND  
PROCESS AGENT**

The board of directors (the “**Board**”) of Cutia Therapeutics (the “**Company**”) announces that Ms. Chan Sze Ting (“**Ms. Chan**”) has tendered her resignation as (1) the company secretary of the Company (the “**Company Secretary**”); (2) the authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); and (3) the agent for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and Rule 19.05(2) of the Listing Rules (the “**Process Agent**”), all with effect from 28 August 2025.

Ms. Chan has confirmed that she has no disagreement with the Board in any respect and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board is pleased to announce that Mr. Leung Chi Kit (“**Mr. Leung**”) has been appointed as the Company Secretary, the Authorised Representative and the Process Agent to fill the vacancy of Ms. Chan, all with effect from 28 August 2025. Mr. Leung, a manager of the Listing Services Department of TMF Hong Kong Limited (a global corporate services provider), has more than 10 years of experience in company secretarial field. Mr. Leung is an associate member of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. Accordingly, Mr. Leung has obtained the professional qualifications as required under Rule 3.28 of the Listing Rules and is capable of discharging the functions of company secretary.

The Board would like to take this opportunity to thank Ms. Chan for her contributions to the Company during her tenure and extend a warm welcome to Mr. Leung on his new appointment.

## **CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

The Board further announces that the Company's principal place of business in Hong Kong has been changed to 31/F, Tower Two, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong with effect from 28 August 2025.

By order of the Board  
**Cutia Therapeutics**  
**Zhang Lele**  
*Chief Executive Officer and Executive Director*

Hong Kong, 28 August 2025

*As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Dr. Huang Xiao and Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Zhang Zhisong and Mr. Ye Xiaoxiang as independent non-executive directors.*